{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:14:55Z","timestamp":1788304495708,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Academician Zhan Qimin Expert Workstation","award":["202405AF140011"],"award-info":[{"award-number":["202405AF140011"]}]},{"name":"Academician Zhan Qimin Expert Workstation","award":["202405AF140011"],"award-info":[{"award-number":["202405AF140011"]}]},{"name":"Academician Zhan Qimin Expert Workstation","award":["202405AF140011"],"award-info":[{"award-number":["202405AF140011"]}]},{"name":"Academician Zhan Qimin Expert Workstation","award":["202405AF140011"],"award-info":[{"award-number":["202405AF140011"]}]},{"name":"Academician Zhan Qimin Expert Workstation","award":["202405AF140011"],"award-info":[{"award-number":["202405AF140011"]}]},{"name":"Academician Zhan Qimin Expert Workstation","award":["202405AF140011"],"award-info":[{"award-number":["202405AF140011"]}]},{"name":"Graduate Education Innovation Fund of Kunming Medical University","award":["2025S301"],"award-info":[{"award-number":["2025S301"]}]},{"name":"Yunnan Provincial Thoracic Oncology Prevention and Treatment Innovative Research Team","award":["202405AS350015"],"award-info":[{"award-number":["202405AS350015"]}]},{"name":"Yunnan Provincial Thoracic Oncology Prevention and Treatment Innovative Research Team","award":["202405AS350015"],"award-info":[{"award-number":["202405AS350015"]}]},{"name":"Yunnan Provincial Thoracic Oncology Prevention and Treatment Innovative Research Team","award":["202405AS350015"],"award-info":[{"award-number":["202405AS350015"]}]},{"name":"Yunnan Provincial Thoracic Oncology Prevention and Treatment Innovative Research Team","award":["202405AS350015"],"award-info":[{"award-number":["202405AS350015"]}]},{"name":"Yunnan Provincial Thoracic Oncology Prevention and Treatment Innovative Research Team","award":["202405AS350015"],"award-info":[{"award-number":["202405AS350015"]}]},{"name":"Yunnan Provincial Thoracic Oncology Prevention and Treatment Innovative Research Team","award":["202405AS350015"],"award-info":[{"award-number":["202405AS350015"]}]},{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"publisher","award":["2024J0353, 2024J0245"],"award-info":[{"award-number":["2024J0353, 2024J0245"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"publisher","award":["2024J0353, 2024J0245"],"award-info":[{"award-number":["2024J0353, 2024J0245"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"publisher","award":["2024J0353, 2024J0245"],"award-info":[{"award-number":["2024J0353, 2024J0245"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yunnan Fundamental Research Projects","award":["grant NO. grant NO. 202501CF070028, 202501CF070029"],"award-info":[{"award-number":["grant NO. grant NO. 202501CF070028, 202501CF070029"]}]},{"name":"Yunnan Fundamental Research Projects","award":["grant NO. grant NO. 202501CF070028, 202501CF070029"],"award-info":[{"award-number":["grant NO. grant NO. 202501CF070028, 202501CF070029"]}]},{"name":"Yunnan Fundamental Research Projects","award":["grant NO. grant NO. 202501CF070028, 202501CF070029"],"award-info":[{"award-number":["grant NO. grant NO. 202501CF070028, 202501CF070029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-026-04448-4","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T09:23:34Z","timestamp":1782033814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of tertiary lymphoid structures in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoimmunotherapy: a retrospective study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5383-7242","authenticated-orcid":false,"given":"Tiantian","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihan","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancui","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengguai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"issue":"1","key":"4448_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006. Published 2024 Feb 2.","journal-title":"J Natl Cancer Cent"},{"issue":"9864","key":"4448_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(12)60643-6.","journal-title":"Lancet"},{"issue":"3","key":"4448_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4448_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdy498","volume":"30","author":"K Muro","year":"2019","unstructured":"Muro K, Lordick F, Tsushima T, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):34\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdy498.","journal-title":"Ann Oncol"},{"issue":"7","key":"4448_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","volume":"17","author":"JA Ajani","year":"2019","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(7):855\u201383. https:\/\/doi.org\/10.6004\/jnccn.2019.0033.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10302","key":"4448_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736. (21)01234-4Nov20;398.","journal-title":"Lancet"},{"issue":"1","key":"4448_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ijc.33976","volume":"151","author":"J Liu","year":"2022","unstructured":"Liu J, Li J, Lin W, et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer. 2022;151(1):128\u201337. https:\/\/doi.org\/10.1002\/ijc.33976.","journal-title":"Int J Cancer"},{"issue":"4","key":"4448_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.21037\/atm-22-513","volume":"10","author":"X Shang","year":"2022","unstructured":"Shang X, Zhao G, Liang F, et al. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study proTOcol for a prospective, single-arm, single-center, open-label, phase-II trial (KeysTOne-001). Ann Transl Med. 2022;10(4):229. https:\/\/doi.org\/10.21037\/atm-22-513.","journal-title":"Ann Transl Med"},{"issue":"22","key":"4448_CR9","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med"},{"issue":"9","key":"4448_CR10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(17)30447-3","volume":"18","author":"D Alderson","year":"2017","unstructured":"Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18(9):1249\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(17)30447-3.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4448_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nri1786","volume":"6","author":"F Aloisi","year":"2006","unstructured":"Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammaTOry diseases. Nat Rev Immunol. 2006;6(3):205\u201317. https:\/\/doi.org\/10.1038\/nri1786.","journal-title":"Nat Rev Immunol"},{"issue":"27","key":"4448_CR12","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","volume":"26","author":"MC Dieu-Nosjean","year":"2008","unstructured":"Dieu-Nosjean MC, AnTOine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410\u20137. https:\/\/doi.org\/10.1200\/JCO.2007.15.0284.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4448_CR13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-21-1130","volume":"28","author":"M Lauss","year":"2022","unstructured":"Lauss M, Donia M, Svane IM, J\u00f6nsson G. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy? Clin Cancer Res. 2022;28(9):1751\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1130.","journal-title":"Clin Cancer Res"},{"key":"4448_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.acr.2015.05.001","volume":"128","author":"JD Peske","year":"2015","unstructured":"Peske JD, Woods AB, Engelhard VH. Control of CD8 TNCell Infiltration inTO Tumors by Vasculature and Microenvironment. Adv Cancer Res. 2015;128:263\u2013307. https:\/\/doi.org\/10.1016\/bs.acr.2015.05.001.","journal-title":"Adv Cancer Res"},{"issue":"10","key":"4448_CR15","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman WH, Meylan M, Pupier G, Calvez A, Hernandez I, Saut\u00e8s-Fridman C. Tertiary lymphoid structures and B cells: An intratumoral immunity cycle. Immunity. 2023;56(10):2254\u201369. https:\/\/doi.org\/10.1016\/j.immuni.2023.08.009.","journal-title":"Immunity"},{"key":"4448_CR16","doi-asserted-by":"publisher","unstructured":"\u8463\u4e3d\u5a9b\uff0c\u738b\u71d5\u59ae\uff0c\u9c81\u667a\u8c6a.\u4e09\u7ea7\u6dcb\u5df4\u7ed3\u6784\u5728\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u4e2d\u7684\u7814\u7a76\u8fdb\u5c55[J].\u4e2d\u56fd\u80bf\u7624\u4e34\u5e8a, 2023;50(14)733\u2013739. https:\/\/doi.org\/10.12354\/j.issn.1000-8179.2023.20230338","DOI":"10.12354\/j.issn.1000-8179.2023.20230338"},{"issue":"7791","key":"4448_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy resPOnse. Nature. 2020;577(7791):549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8.","journal-title":"Nature"},{"issue":"6","key":"4448_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/cas.14023","volume":"110","author":"S Kuwabara","year":"2019","unstructured":"Kuwabara S, Tsuchikawa T, Nakamura T, et al. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Cancer Sci. 2019;110(6):1853\u201362. https:\/\/doi.org\/10.1111\/cas.14023.","journal-title":"Cancer Sci"},{"issue":"4","key":"4448_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1084\/jem.20131737","volume":"211","author":"H Fleige","year":"2014","unstructured":"Fleige H, Ravens S, Moschovakis GL, et al. IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med. 2014;211(4):643\u201351. https:\/\/doi.org\/10.1084\/jem.20131737.","journal-title":"J Exp Med"},{"issue":"12","key":"4448_CR20","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839\u201344. https:\/\/doi.org\/10.1038\/s41591-020-1085-z.","journal-title":"Nat Med"},{"issue":"7791","key":"4448_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reyni\u00e8s A, Keung EZ, et al. B cells are associated with survival and immunotherapy resPOnse in sarcoma. Nature. 2020;577(7791):556\u201360. https:\/\/doi.org\/10.1038\/s41586-019-1906-8.","journal-title":"Nature"},{"issue":"12","key":"4448_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/ni.3290","volume":"16","author":"S Finkin","year":"2015","unstructured":"Finkin S, Yuan D, Stein I, et al. EcTOpic lymphoid structures function as microniches for tumor progeniTOr cells in hepaTOcellular carcinoma. Nat Immunol. 2015;16(12):1235\u201344. https:\/\/doi.org\/10.1038\/ni.3290.","journal-title":"Nat Immunol"},{"issue":"1","key":"4448_CR23","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/s41467-022-29701-x","volume":"13","author":"S Fleig","year":"2022","unstructured":"Fleig S, Kapanadze T, Bernier-Latmani J, et al. Loss of vascular endothelial notch signaling promotes spontaneous formation of tertiary lymphoid structures. Nat Commun. 2022;13(1):2022. https:\/\/doi.org\/10.1038\/s41467-022-29701-x. Published 2022 Apr 19.","journal-title":"Nat Commun"},{"issue":"5","key":"4448_CR24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jcmgh.2021.06.023","volume":"12","author":"FR Delvecchio","year":"2021","unstructured":"Delvecchio FR, Fincham REA, Spear S, et al. Pancreatic Cancer Chemotherapy Is POtentiated by Induction of Tertiary Lymphoid Structures in Mice. Cell Mol Gastroenterol HepaTOl. 2021;12(5):1543\u201365. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.06.023.","journal-title":"Cell Mol Gastroenterol HepaTOl"},{"issue":"12","key":"4448_CR25","doi-asserted-by":"publisher","first-page":"e157215","DOI":"10.1172\/jci.insight.157215","volume":"7","author":"M Ukita","year":"2022","unstructured":"Ukita M, Hamanishi J, YoshiTOmi H, et al. CXCL13-producing CD4\u2009+\u2009T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight. 2022;7(12):e157215. https:\/\/doi.org\/10.1172\/jci.insight.157215. Published 2022 Jun 22.","journal-title":"JCI Insight"},{"issue":"9","key":"4448_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1084\/jem.20021761","volume":"197","author":"DL DrayTOn","year":"2003","unstructured":"DrayTOn DL, Ying X, Lee J, Lesslauer W, Ruddle NH. EcTOpic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J Exp Med. 2003;197(9):1153\u201363. https:\/\/doi.org\/10.1084\/jem.20021761.","journal-title":"J Exp Med"},{"key":"4448_CR27","doi-asserted-by":"publisher","first-page":"120333","DOI":"10.1016\/j.ijpharm.2021.120333","volume":"598","author":"S Wu","year":"2021","unstructured":"Wu S, Liu D, Li W, et al. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death. Int J Pharm. 2021;598:120333. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120333.","journal-title":"Int J Pharm"},{"issue":"4","key":"4448_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245. Published 2012 Mar 15.","journal-title":"Nat Rev Cancer"},{"key":"4448_CR29","doi-asserted-by":"publisher","unstructured":"Li H, Liu H, Fu H et al. Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With HepaTOcellular Carcinoma. Front Immunol. 2021;12:648812. Published 2021 May 26. https:\/\/doi.org\/10.3389\/fimmu.2021.648812","DOI":"10.3389\/fimmu.2021.648812"},{"issue":"11","key":"4448_CR30","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00262-019-02407-8","volume":"68","author":"M SofoPOulos","year":"2019","unstructured":"SofoPOulos M, Fortis SP, Vaxevanis CK, et al. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. Cancer Immunol Immunother. 2019;68(11):1733\u201345. https:\/\/doi.org\/10.1007\/s00262-019-02407-8.","journal-title":"Cancer Immunol Immunother"},{"key":"4448_CR31","doi-asserted-by":"publisher","first-page":"1166497","DOI":"10.3389\/fimmu.2023.1166497","volume":"14","author":"T Shang","year":"2023","unstructured":"Shang T, Jiang T, Lu T, et al. Tertiary lymphoid structures predict the prognosis and immunotherapy resPOnse of cholangiocarcinoma. Front Immunol. 2023;14:1166497. https:\/\/doi.org\/10.3389\/fimmu.2023.1166497. Published 2023 May 10.","journal-title":"Front Immunol"},{"issue":"6","key":"4448_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","volume":"28","author":"A Italiano","year":"2022","unstructured":"Italiano A, Bessede A, Pulido M, et al. Pembrolizumab in sofTNtissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022;28(6):1199\u2013206. https:\/\/doi.org\/10.1038\/s41591-022-01821-3.","journal-title":"Nat Med"},{"key":"4448_CR33","doi-asserted-by":"publisher","unstructured":"\u674e\u6885\uff0c\u738b\u71d5\u59ae\uff0c\u9648\u66e6\u7b49.\u98df\u7ba1\u9cde\u764c\u4e2d\u4e09\u7ea7\u6dcb\u5df4\u7ed3\u6784\u7684\u8868\u8fbe\u7279\u5f81\u53ca\u4e34\u5e8a\u610f\u4e49[J].\u80bf\u7624\u7efc\u5408\u6cbb\u7597\u7535\u5b50\u6742\u5fd7, 2023;9(4):27\u201333. https:\/\/doi.org\/10.12151\/JMCM.2023.04-06","DOI":"10.12151\/JMCM.2023.04-06"},{"key":"4448_CR34","doi-asserted-by":"publisher","unstructured":"\u725b\u632f\u5c79,\u91d1\u6da6\u68ee,\u989c\u514b\u9e4f\u7b49.\u4e09\u7ea7\u6dcb\u5df4\u7ed3\u6784\u5728\u98df\u7ba1\u9cde\u72b6\u7ec6\u80de\u764c\u9884\u540e\u53ca\u514d\u75ab\u6cbb\u7597\u4e2d\u7684\u7814\u7a76\u8fdb\u5c55[J].\u4e2d\u56fd\u80f8\u5fc3\u8840\u7ba1\u5916\u79d1\u4e34\u5e8a\u6742\u5fd7, 2026;33(3):468\u2013474. https:\/\/doi.org\/10.7507\/1007-4848.202403018","DOI":"10.7507\/1007-4848.202403018"},{"issue":"11","key":"4448_CR35","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00262-019-02407-8","volume":"68","author":"M SofoPOulos","year":"2019","unstructured":"SofoPOulos M, Fortis SP, Vaxevanis CK, et al. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. Cancer Immunol Immunother. 2019;68(11):1733\u201345. https:\/\/doi.org\/10.1007\/s00262-019-02407-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"4448_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","volume":"34","author":"M Frelaut","year":"2020","unstructured":"Frelaut M, du Rusquec P, de Moura A, Le TOurneau C, Borcoman E. Pseudoprogression and Hyperprogression as New Forms of ResPOnse TO Immunotherapy. BioDrugs. 2020;34(4):463\u201376. https:\/\/doi.org\/10.1007\/s40259-020-00425-y.","journal-title":"BioDrugs"},{"issue":"3","key":"4448_CR37","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","volume":"76","author":"GY Ding","year":"2022","unstructured":"Ding GY, Ma JQ, Yun JP, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J HepaTOl. 2022;76(3):608\u201318. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.030.","journal-title":"J HepaTOl"},{"issue":"6","key":"4448_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"4448_CR39","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-023-02235-9","volume":"128","author":"Y Hayashi","year":"2023","unstructured":"Hayashi Y, Makino T, SaTO E, et al. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and resPOnse TO immune checkPOint inhibiTOrs. Br J Cancer. 2023;128(12):2175\u201385. https:\/\/doi.org\/10.1038\/s41416-023-02235-9.","journal-title":"Br J Cancer"},{"issue":"8","key":"4448_CR40","doi-asserted-by":"publisher","first-page":"e1346","DOI":"10.1002\/ctm2.1346","volume":"13","author":"Q Wang","year":"2023","unstructured":"Wang Q, Sun K, Liu R, et al. Single-cell transcripTOme sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy. Clin Transl Med. 2023;13(8):e1346. https:\/\/doi.org\/10.1002\/ctm2.1346.","journal-title":"Clin Transl Med"},{"issue":"7791","key":"4448_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/d41586-019-03943-0","volume":"577","author":"TC Bruno","year":"2020","unstructured":"Bruno TC. New predicTOrs for immunotherapy resPOnses sharpen our view of the tumour microenvironment. Nature. 2020;577(7791):474\u20136. https:\/\/doi.org\/10.1038\/d41586-019-03943-0.","journal-title":"Nature"},{"issue":"1","key":"4448_CR42","doi-asserted-by":"publisher","first-page":"1883890","DOI":"10.1080\/2162402X.2021.1883890","volume":"10","author":"C Pan","year":"2021","unstructured":"Pan C, Wang Y, Liu Q, et al. Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma. Oncoimmunology. 2021;10(1):1883890. https:\/\/doi.org\/10.1080\/2162402X.2021.1883890. Published 2021 Feb 10.","journal-title":"Oncoimmunology"},{"issue":"6","key":"4448_CR43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4448_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41379-018-0113-8","volume":"32","author":"M Lee","year":"2019","unstructured":"Lee M, Heo SH, Song IH, et al. Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. Mod Pathol. 2019;32(1):70\u201380. https:\/\/doi.org\/10.1038\/s41379-018-0113-8.","journal-title":"Mod Pathol"},{"key":"4448_CR45","doi-asserted-by":"publisher","unstructured":"\u8d75\u96ea\u6960 \u90ed\u65ed\u5cf0. \u4e01\u6210\u667a, \u9648\u4e1c\u4e1c, \u97e6\u4e3d\u745e, \u674e\u6668, \u79e6\u8d35\u519b, \u738b\u5a07. \u4f53\u8d28\u91cf\u6307\u6570\u5bf9\u98df\u7ba1\u9cde\u764c\u60a3\u8005\u672f\u540e\u5e76\u53d1\u75c7\u548c\u957f\u671f\u9884\u540e\u7684\u5f71\u54cd[J] \u5929\u6d25\u533b\u836f. 2023;51(10):1131\u20135. https:\/\/doi.org\/10.11958\/20230090","DOI":"10.11958\/20230090"},{"key":"4448_CR46","doi-asserted-by":"publisher","first-page":"1757530","DOI":"10.3389\/or.2026.1757530","volume":"20","author":"K Li","year":"2026","unstructured":"Li K, Lu S, Li C, et al. Evaluating the role of BMI in survival and complications in older esophageal squamous cell carcinoma following esophagectomy. Oncol Rev. 2026;20:1757530. https:\/\/doi.org\/10.3389\/or.2026.1757530. Published 2026 Feb 23.","journal-title":"Oncol Rev"},{"issue":"7791","key":"4448_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1914-8","journal-title":"Nature"},{"issue":"7791","key":"4448_CR48","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922.","journal-title":"Nature"},{"issue":"3","key":"4448_CR49","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","volume":"76","author":"GY Ding","year":"2022","unstructured":"Ding GY, Ma JQ, Yun JP, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol. 2022;76(3):608\u201318. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.030.","journal-title":"J Hepatol"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-04448-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04448-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04448-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:28:18Z","timestamp":1788301698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13019-026-04448-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4448"],"URL":"https:\/\/doi.org\/10.1186\/s13019-026-04448-4","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Ethics Committee of the Third Affiliated Hospital of Kunming Medical University, Review Number: KYLX2025-355.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"665"}}